Redeye has updated its near-term estimates following Kontigo Care's Q2 report and maintains a positive view on the case. Recent multi-year municipal wins and Nordic partnerships highlight the scalable potential of its MDR-certified Previct® platform. With the bottom behind it, the company is positioned for growth, with sales expected to accelerate in Q3 and a strong foundation for recurring revenue supported by several near-term potential catalysts.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/